Similar articles for PMID: 26951625

Year	Number of Results
2002	1
2006	4
2008	1
2009	2
2010	1
2011	3
2012	7
2013	14
2014	15
2015	13
2016	12
2017	18
2018	9
2019	9
2020	5
2021	7
2022	10
2023	3
2024	0

1

Ocular toxicities of MEK inhibitors and other targeted therapies.

Stjepanovic N, Velazquez-Martin JP, Bedard PL. Stjepanovic N, et al. Ann Oncol. 2016 Jun;27(6):998-1005. doi: 10.1093/annonc/mdw100. Epub 2016 Mar 6. Ann Oncol. 2016. PMID: 26951625 Free article. Review.

2

New features in MEK retinopathy.

Tyagi P, Santiago C. Tyagi P, et al. BMC Ophthalmol. 2018 Sep 14;18(Suppl 1):221. doi: 10.1186/s12886-018-0861-8. BMC Ophthalmol. 2018. PMID: 30255823 Free PMC article.

3

MEK inhibitors: a new class of chemotherapeutic agents with ocular toxicity.

Duncan KE, Chang LY, Patronas M. Duncan KE, et al. Eye (Lond). 2015 Aug;29(8):1003-12. doi: 10.1038/eye.2015.82. Epub 2015 Jun 5. Eye (Lond). 2015. PMID: 26043707 Free PMC article. Review.

4

Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management.

Manousaridis I, Mavridou S, Goerdt S, Leverkus M, Utikal J. Manousaridis I, et al. J Eur Acad Dermatol Venereol. 2013 Jan;27(1):11-8. doi: 10.1111/j.1468-3083.2012.04546.x. Epub 2012 Apr 28. J Eur Acad Dermatol Venereol. 2013. PMID: 22540151 Review.

5

Cutaneous adverse effects of targeted therapies: Part II: Inhibitors of intracellular molecular signaling pathways.

Macdonald JB, Macdonald B, Golitz LE, LoRusso P, Sekulic A. Macdonald JB, et al. J Am Acad Dermatol. 2015 Feb;72(2):221-36; quiz 237-8. doi: 10.1016/j.jaad.2014.07.033. J Am Acad Dermatol. 2015. PMID: 25592339 Review.

6

OCULAR ADVERSE EVENTS ASSOCIATED WITH MEK INHIBITORS.

Méndez-Martínez S, Calvo P, Ruiz-Moreno O, Pardiñas Barón N, Leciñena Bueno J, Gil Ruiz MDR, Pablo L. Méndez-Martínez S, et al. Retina. 2019 Aug;39(8):1435-1450. doi: 10.1097/IAE.0000000000002451. Retina. 2019. PMID: 30681641 Review.

7

MEK inhibitors: a new class of chemotherapeutic agents with ocular toxicity.

Maubon L, Hirji N, Petrarca R, Ursell P. Maubon L, et al. Eye (Lond). 2016 Feb;30(2):330. doi: 10.1038/eye.2015.243. Epub 2015 Nov 20. Eye (Lond). 2016. PMID: 26584794 Free PMC article. No abstract available.

8

Targeted agents: management of dermatologic toxicities.

Burtness B. Burtness B. J Natl Compr Canc Netw. 2014 May;12(5 Suppl):793-6. doi: 10.6004/jnccn.2014.0192. J Natl Compr Canc Netw. 2014. PMID: 24853219

9

Effect of inhibition of the FGFR-MAPK signaling pathway on the development of ocular toxicities.

van der Noll R, Leijen S, Neuteboom GH, Beijnen JH, Schellens JH. van der Noll R, et al. Cancer Treat Rev. 2013 Oct;39(6):664-72. doi: 10.1016/j.ctrv.2013.01.003. Epub 2013 Feb 19. Cancer Treat Rev. 2013. PMID: 23434072 Review.

10

Emerging MEK inhibitors.

McCubrey JA, Steelman LS, Abrams SL, Chappell WH, Russo S, Ove R, Milella M, Tafuri A, Lunghi P, Bonati A, Stivala F, Nicoletti F, Libra M, Martelli AM, Montalto G, Cervello M. McCubrey JA, et al. Expert Opin Emerg Drugs. 2010 Jun;15(2):203-23. doi: 10.1517/14728210903282760. Expert Opin Emerg Drugs. 2010. PMID: 20151845 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

118 results

Results by year